Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INVECTA

Financiado

Cerrado

Integrative characterisation of Novel adenovirus VECtors aimed at Therapeutic Ap...

Integrative characterisation of Novel adenovirus VECtors aimed at Therapeutic Applications Adenovirus based vectors have potential translational and commercial values and are studied as vectors for gene transfer and vaccination . Low seroprevalence adenoviruses are efficacious platforms for vector design, warranting the... ver más

30/11/2027

RBI

198K€

Presupuesto del proyecto: 198K€

Líder del proyecto

RUDER BOSKOVIC INSTITUTE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-09-22

HORIZON-MSCA-2022-SE-01-01: MSCA Staff Exchanges 2022 Expected Outcome:

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

RBI

59.80K€ | Lider

CSIC

50.60K€ | Participante

ACCESSION THERAPEUTICS LIMIT...

N.D. | Participante

46.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 50 meses Fecha Inicio: 2023-09-22
Fecha Fin: 2027-11-30

Líder del proyecto

RUDER BOSKOVIC INSTITUTE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 198K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Adenovirus based vectors have potential translational and commercial values and are studied as vectors for gene transfer and vaccination . Low seroprevalence adenoviruses are efficacious platforms for vector design, warranting their thorough investigation. Therefore, the main objective of INVECTA is to establish a collaborative effort for the study of scientific problems related to development of novel low seroprevalence adenovirus based vectors aimed at their therapeutic usage, with an emphasis on training both experienced and early stage researchers in adenovirus research, as well as establishing foundation for long term collaboration. As the use of adenoviral based platforms becomes widespread there is a pressing need to develop protocols and methodologies to define the full complement of adenovirus-host interactions, the adenoviral interactome, that may limit efficacy and compromise safety. Within INVECTA we aim to increase our understanding of novel low seroprevalence adenovirus vectors with respect to infectivity, structure, stability, receptor usage, tropism, and the interaction with the blood and immune system. This knowledge will allow us to evaluate novel low seroprevalence vectors at the pre-clinical level in areas of unmet clinical need, namely cancer gene therapy and vaccination. INVECTA presents an interdisciplinary and intersectoral network in basic and translational adenovirus research which will foster transfer of knowledge, skills and technology, as well as enable training in the field of basic and applicative adenovirus biology. To maximize knowledge sharing, INVECTA will second researchers within consortium, organize internal workshops and training sessions, and strongly encourage participation in specialized workshops, schools and conferences according to the open science model.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores